AMY DAVIS: Open Payments
NPI 1417214909 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,437 in 59 payments from 34 companies in 2025. Trend: 2023 $384 · 2024 $726 · 2025 $1,437
Food & beverage: $1,437
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 6 | $178 |
| AstraZeneca Pharmaceuticals LP | 4 | $119 |
| PharmaEssentia USA Corporation | 4 | $81 |
| SOBI, INC | 3 | $76 |
| Lilly USA, LLC | 3 | $75 |
| Genentech USA, Inc. | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $59 |
| Iovance Biotherapeutics, Inc. | 2 | $58 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $49 |
Products named: KEYTRUDA, BESREMI, TEVIMBRA, Enhertu, VERZENIO, Onivyde, Amtagvi, Vyloy.
Industry payments across GA — which companies pay providers there.
